Obesity PreventionNCT06619028
External Body Weight Effects on Body Weight in Adults With Grade II and III Obesity
A study testing Weighted vest in people with Obesity Prevention and Obesity, run by Escoles Universitaries Gimbernat at 1 site in Spain.
Trial summary
Obesity is a growing problem in industrialized societies. This condition is associated with an increase in metabolic and cardiovascular diseases. Its cause is multifactorial, influenced by the environment, excessive calorie consumption, insufficient physical activity, sedentary lifestyle and alterations in energy… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity Prevention, Obesity
- What is being tested?
- Weighted vest
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteSpain
- Study dates
- 1 Oct 2024to 1 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age\>18 years
- BMI (≥35)
- Compliance at intervention delivery.
Who cannot join
- Chronic pathology that may hinder the performance of the intervention
- Chronic pain
- Regular consumption of pharmacology or supplementation that affects body weight
- Inability to perform any physical activity or high risk of suffering adverse effects from the interventibariatric-metabolic surgery
- Reduced mobility
- Changes of 5kg or more in the last 3 months
Show all 9Show fewer
- Drastic changes in lifestyle habits in the last 3 months (physical activity, eating habits, nicotine or alcohol consumption)
- Apparent risk of not being able to complete the study intervention (at the principal investigator\'s discretion)
- Pregnancy
Trial locations and contacts
1 site in 1 country.
Spain1 site
EUGimbernat
Sant Cugat del Vallès, Barcelona, 08174
Manuel Garcia-San-Emeterio, PhD Student, +34689608040, manuel.garcias@eug.es
About this study
Official title: Effectiveness of the Use of External Body Weight in the Regulation of Body Weight, Body Composition and Analytical Parameters in Adults With Grade II and III Obesity
Obesity is a growing problem in industrialized societies. This condition is associated with an increase in metabolic and cardiovascular diseases. Its cause is multifactorial, influenced by the environment, excessive calorie consumption, insufficient physical activity, sedentary lifestyle and alterations in energy metabolism.
In this context, the hormone leptin, responsible for regulating appetite and body weight, presents resistance in people with obesity, altering the metabolic balance. Recent research has explored the concept of the "gravitostat", a system that responds to the mechanical stimulus of standing upright, as a promising approach in the regulation of body weight. Animal and human studies have shown positive results in weight loss and body recomposition using this system. However, more research is needed to evaluate the clinical applicability and effectiveness of the gravitostat in the management of obesity.
For this reason, the present study is proposed, with a prospective longitudinal controlled design in the use of external body weight (where the patients are their own control: intrasubject controlled study) during 4 weeks, with a previous control period of 4 weeks and a follow-up of 4 weeks. The proposed objectives are to analyze the effectiveness of the use of external weight in the regulation of body weight, body composition and analytical parameters in people with grade II and III obesity. In this way, to analyze the clinical applicability of the gravitostat in the management of patients with this metabolic pathology.
Read the detailed description
BACKGROUND Obesity is one of the most prevalent and booming health and social problems in recent decades in industrialized societies. Obesity rates in European countries such as the United Kingdom, Germany, France and Spain fluctuate between 23 and 29% in the adult population, according to the World Health Organization (WHO). These values increase to 42.4%, 27% and 31% in the United States, Canada and Australia, respectively, considering data from the last 5 years from the main health agencies of these countries, making it a social and public health problem.
The etiopathogenesis of this condition is multifactorial; the obesogenic characteristics of the environment can influence gene expression conditioning the development of obesity. Increased caloric intake, influenced by high-fat diets (Westerns\' diet), the absence or insufficiency of physical activity and alterations in energy metabolism seem to be the three fundamental factors contributing to the development of obesity. Moreover, these factors seem to play a major role in the development of other metabolic entities such as hypertension, dyslipidemia and insulin resistance or type II diabetes, which, together with central obesity, make up the metabolic syndrome. This clinical entity doubles the risk of coronary and cerebrovascular disease, increases the risk of diabetes fivefold, and increases all-cause mortality by 50%. In parallel to the risk factors listed above, some studies highlight the role of a sedentary lifestyle as a factor independent of physical activity in contributing to the development of metabolic pathology. Not only the absence of low, moderate or high intensity physical activity has been correlated with the development of metabolic syndrome, but also the increase in time spent in sedentary activities, with an odds ratio of 2.38.
These intrinsic and extrinsic factors seem to interact and condition each other, altering homeostatic and physiological processes in obese individuals.
Since its discovery and description in the 1990s by Friedman leptin has been the most important hormonal factor in the regulation and control of caloric intake and metabolism, and consequently of body weight and composition. Its peripheral production at the level of white fat tissue and its hypothalamic effects (decrease in orexic neuronal activity and conditioning of dopaminergic reward circuits) condition the individual\'s response to food, regulating satiety and intake.
Evidence shows that this mechanism is altered in people with obesity where excessive leptin production, due to increased concentrations of fat tissue, and consequently high serum concentrations, condition central and peripheral sensitivity to this hormone, generating, in the long run, lower response efficiency, giving rise to the term "leptin resistance ". This resistance seems to modify the hypothalamic satiety signal, as well as the dopaminergic circuits associated with food intake,predisposing to the appearance or increase of metabolic pathology, especially obesity. This dysregulation in caloric intake appears without alterations in the production and function of ghrelin, a hormone produced in the stomach associated with hunger.
Recent research has proposed a second system of body weight homeostasis associated with the mechanical stimulus of standing upright, coined the term "gravitostat ".
Studies in mice and in humans show promising results in the regulation of body weight and fat percentage by this mechanical system. These investigations have shown significant reductions in both parameters when external weight is added to the study subjects, generating modifications in food intake and caloric expenditure. These adaptations have been tested independently of leptin resistance or the lack of leptin receptors, thus demonstrating the existence of an independent homeostatic regulation pathway. These changes have been shown to be significant only in obese subjects, whereas in normopese subjects, who show greater sensitivity to leptin, the changes produced by the increased load do not appear to be significant. Regarding body recomposition, these studies seem to indicate a maintenance of muscle mass, without experiencing significant losses, as in other contexts of caloric deficit thus prioritizing the loss of white fat tissue (especially visceral) as a mechanism of weight regulation.
Some studies justify this action by the production of fibroblast growth factors (FGF) produced by the osteocytes, specifically, the factor FGF21 associated with the hypothalamic receptor FGFR1c. The triplication in the serum quantities of FGF21 factor, by hepatic expression, in subjects exposed to body weight, seems to justify the increase in fat mobilization and oxidation, as well as the loss of body weight, which, despite the catabolic context, does not affect muscle mass. In any case, the results do not yet seem to be conclusive, since at supraphysiological loads of FGF21 the action of weight loss is mitigated, probably indicating a regulation by the FGFR1c receptor mediated, in part, by one or more other factors. This could be a key factor in the lack of effectiveness in normopese individuals.
Some stuides show how the increased load during the prepubertal period in rats reduces the expression of hormones associated with growth (IGF-1 and GHGH) as a homeostatic mechanism to control sudden weight gain. Similarly, down-regulation of ghrelin receptors at the hypothalamic level is observed, leading to a decrease in caloric intake. Other adaptations that could explain the physiological mechanism of body homeostasis, in this case, during growth.
With respect to analytical parameters, the only clinical trial carried out in humans only shows significant reductions in LDL and leptin; the results are inconclusive for the other parameters studied.
Taking this into consideration, some evidence observed a bidirectional regulation, with increases in body weight and fat mass in subjects with the sudden decrease in load. The lack of follow-up in human studies4 does not allow extrapolation of these results. At the clinical level, this regulation could justify weight and, essentially, fat gain after liposuction interventions6 or other contexts of abrupt weight loss or dietary patterns with aggressive caloric restriction. In this case, both homeostatic systems would influence, on the one hand, the gravitostat would increase food intake and the decrease in adipose tissue and the conditioned reduction in leptin production would decrease anorexic signals, predisposing the subjects to have more frequent and calorically dense intakes.
The results presented by some reserchers are promising in the development of new tools to help patients with obesity, despite this, the short duration of the intervention and the lack of follow-up of the patients, the lack of consistent changes in the analytical analysis, the performance only in young and moderately obese patients, as well as the high demand of the intervention protocol and the sudden gain in body weight after the intervention (in basic studies) make further research necessary to prove the applicability, usefulness and effectiveness of the gravitostat as a therapeutic tool, as well as the high demands of the intervention protocol and the sudden gain of body weight after the intervention (in basic studies) make it necessary to carry out further research to prove the applicability, usefulness and effectiveness of the gravitostat as a therapeutic tool in patients with obesity.
For this reason, the present doctoral thesis proposes an intrasubject controlled study for a period of 12 weeks (4 control, 4 intervention and 4 follow-up) in patients with grade II and III obesity. During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention, they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle.
For this study, accepting an alpha risk of 0.05 and a beta risk of less than 0.2 in a unilateral contrast, 24 patients are required to detect a difference equal to or greater than 0.15 unit. A common standard deviation of 1.4 and a correlation between the first and second measurement of 0.99 (according to literature) is assumed. A loss rate of 10% is assumed. Patients will be recruited from the endocrinology service of the Hospital Universitario Parc Taulí.
- Conditions
- Obesity Prevention, Obesity
- Being tested
- Weighted vest
- Keywords
- Obesity, Body Weight, Weight loss, Treatment, Leptin, Gravitostat
- Medical subject headings
- Obesity, Body Weight, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Weighted vestDevice
Also called External load
During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group (IG) | Experimental | During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest. Receives: Device: Weighted vest |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body weight
Measured fasting weight by electronic scale (BC-545N Tanita)
Measured: From enrollment to the end of treatment at 12 weeks
Secondary outcomes (11)
Nutritional state
Short Dietary Questionnaire Punctuation: From 0 to 9. Interpretation: Higher results, better adherence with Mediterranean diet. Lower results, worst adherence with Mediterranean diet.
Measured: From enrollment to the end of treatment at 12 weeks
Grip Strength
Measuring tool: Grip Strength Dynamometer Takei T.K.K 5401 Procedure: 3 consecutive measurements with each extremity, taking the mean as reference value for each.
Measured: From enrollment to the end of treatment at 12 weeks
Lower Extremity Strength
30' chair stand-up test Test performed only once, with a 43 cm (17 inches) high chair without armrests.
Measured: From enrollment to the end of treatment at 12 weeks
Activity state
Minnesota Leisure Time Physical Activity Questionnaire No standared punctuation Higher values associated with higher activity state Punctuation registred in minutes, days, months.
Measured: From enrollment to the end of treatment at 12 weeks
Absolute frequency of patients reporting adverse effects
Self-reported ad hoc questionnaire following CTCAE v4.0 criteria
Measured: From week 4 to the end of treatment at 12 weeks
Body compostiton
Bioimpedance electrical analysis (BC-545N Tanita) Body fat percentage; no standarized values, lower values are better. Muscle mass percentatge; no standarized values, higher values are better. Bone mass level; no standarized values, higher values are better. Visceral fat level; no standarized values, lower values are better.
Measured: From enrollment to the end of treatment at 12 weeks
Body compostiton
Ultrasound measurement of muscle cross-sectional area and fat folds in thigh and abdomen (General Electric VScan) Muscle cross-sectional area: mesured (midpoint from anterosuperior iliac spine and superior pole of patella). 3 mesurements, mean result.
Fat fold: mesured (midpoint from anterosuperior iliac spine and superior pole of patella). 3 mesurements, mean result.
Fat fold: mesured (2cm below the umbilicus; subumbilical area). 3 mesurements, mean result.
Measured: From enrollment to the end of treatment at 12 weeks
Age
Measured in ages using a self-reported questionnaire.
Measured: Baseline
Sex
Measured in dichotomous variable using a self-reported questionnaire.
Measured: Baseline
Height
Measurement in centimeters using tape measure
Measured: Baseline
Body Mass Index
Calculated by height in meters and weight in kilograms. Following this formula: BMI = weight ÷ height^2 (units: kg/m^2)
Fallowing this criteria to interpret:
- lt; 16.0 Severely Underweight 16.0 - 18.4 Underweight 18.5 - 24.9 Normal 25.0 - 29.9 Overweight 30.0 - 34.9 Type I Obesity 35.0 - 39.9 Type II Obesity
- gt; 40.0 Type III Obesity
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start1 Oct 2024 (estimated)
- Primary completion1 Jul 2025 (estimated)
- Study completion1 Jul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Obesity PreventionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Model description
- A prospective longitudinal controlled design on the use of external body weight (where patients are their own control: intrasubject controlled study) for 4 weeks, with a 4-week pre-control period and a 4-week follow-up.
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Escoles Universitaries Gimbernat
- Sponsor type
- University, hospital or other
- Collaborators
- Corporacion Parc Tauli
- Responsible party
- Sponsor
- Investigators
- Maria Assumpta Caixàs Pedragós, PhD, MD, Principal investigator, Consorci Sanitari Parc Taulí
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06619028
- Sponsor's protocol ID
- G0001
- Status last verified
- Sep 2024
- First submitted
- 13 Sep 2024
- Last updated
- 1 Oct 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Palsdottir V, Windahl SH, Hagg DA, Keantar H, Bellman J, Buchanan A, Vaughan TJ, Linden D, Jansson JO, Ohlsson C. Interactions Between the Gravitostat and the Fibroblast Growth Factor System for the Regulation of Body Weight. Endocrinology. 2019 May 1;160(5):1057-1064. doi: 10.1210/en.2018-01002.
PubMed 30888399Bake T, Peris-Sampedro F, Waczek Z, Ohlsson C, Palsdottir V, Jansson JO, Dickson SL. The gravitostat protects diet-induced obese rats against fat accumulation and weight gain. J Neuroendocrinol. 2021 Aug;33(8):e12997. doi: 10.1111/jne.12997. Epub 2021 Jul 9.
PubMed 34240761Jansson JO, Dalmau Gasull A, Schele E, Dickson SL, Palsdottir V, Palmquist A, Girones FF, Bellman J, Anesten F, Hagg D, Ohlsson C. A Body Weight Sensor Regulates Prepubertal Growth via the Somatotropic Axis in Male Rats. Endocrinology. 2021 Jun 1;162(6):bqab053. doi: 10.1210/endocr/bqab053.
PubMed 33693673Jansson JO, Palsdottir V, Hagg DA, Schele E, Dickson SL, Anesten F, Bake T, Montelius M, Bellman J, Johansson ME, Cone RD, Drucker DJ, Wu J, Aleksic B, Tornqvist AE, Sjogren K, Gustafsson JA, Windahl SH, Ohlsson C. Body weight homeostat that regulates fat mass independently of leptin in rats and mice. Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):427-432. doi: 10.1073/pnas.1715687114. Epub 2017 Dec 26.
PubMed 29279372Ohlsson C, Hagg DA, Hammarhjelm F, Dalmau Gasull A, Bellman J, Windahl SH, Palsdottir V, Jansson JO. The Gravitostat Regulates Fat Mass in Obese Male Mice While Leptin Regulates Fat Mass in Lean Male Mice. Endocrinology. 2018 Jul 1;159(7):2676-2682. doi: 10.1210/en.2018-00307.
PubMed 29800288Ohlsson C, Gidestrand E, Bellman J, Larsson C, Palsdottir V, Hagg D, Jansson PA, Jansson JO. Increased weight loading reduces body weight and body fat in obese subjects - A proof of concept randomized clinical trial. EClinicalMedicine. 2020 Apr 30;22:100338. doi: 10.1016/j.eclinm.2020.100338. eCollection 2020 May.
PubMed 32510046Ekblom O, Ekblom-Bak E, Rosengren A, Hallsten M, Bergstrom G, Borjesson M. Cardiorespiratory Fitness, Sedentary Behaviour and Physical Activity Are Independently Associated with the Metabolic Syndrome, Results from the SCAPIS Pilot Study. PLoS One. 2015 Jun 29;10(6):e0131586. doi: 10.1371/journal.pone.0131586. eCollection 2015.
PubMed 26120842Gallardo-Alfaro L, Bibiloni MDM, Mascaro CM, Montemayor S, Ruiz-Canela M, Salas-Salvado J, Corella D, Fito M, Romaguera D, Vioque J, Alonso-Gomez AM, Warnberg J, Martinez JA, Serra-Majem L, Estruch R, Fernandez-Garcia JC, Lapetra J, Pinto X, Garcia Rios A, Bueno-Cavanillas A, Gaforio JJ, Matia-Martin P, Daimiel L, Mico-Perez RM, Vidal J, Vazquez C, Ros E, Fernandez-Lazaro CI, Becerra-Tomas N, Gimenez-Alba IM, Zomeno MD, Konieczna J, Compan-Gabucio L, Tojal-Sierra L, Perez-Lopez J, Zulet MA, Casanas-Quintana T, Castro-Barquero S, Gomez-Perez AM, Santos-Lozano JM, Galera A, Basterra-Gortari FJ, Basora J, Saiz C, Perez-Vega KA, Galmes-Panades AM, Tercero-Macia C, Sorto-Sanchez C, Sayon-Orea C, Garcia-Gavilan J, Munoz-Martinez J, Tur JA. Leisure-Time Physical Activity, Sedentary Behaviour and Diet Quality are Associated with Metabolic Syndrome Severity: The PREDIMED-Plus Study. Nutrients. 2020 Apr 7;12(4):1013. doi: 10.3390/nu12041013.
PubMed 32272653Berthoud HR, Morrison CD, Munzberg H. The obesity epidemic in the face of homeostatic body weight regulation: What went wrong and how can it be fixed? Physiol Behav. 2020 Aug 1;222:112959. doi: 10.1016/j.physbeh.2020.112959. Epub 2020 May 16.
PubMed 32422162
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of the Use of External Body Weight in the Regulation of Body Weight, Body Composition and Analytical Parameters in Adults With Grade II and III Obesity
- ClinicalTrials.gov ID
- NCT06619028
- Acronym / sponsor ID
- G0001
- Conditions
- Obesity Prevention, Obesity
- Keywords
- Obesity, Body Weight, Weight loss, Treatment, Leptin, Gravitostat
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Escoles Universitaries GimbernatUniversity, hospital or other
- Collaborators
- Corporacion Parc Tauli
- Study start
- 1 Oct 2024 (estimated)
- Primary completion
- 1 Jul 2025 (estimated)
- Study completion
- 1 Jul 2025 (estimated)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity is a growing problem in industrialized societies. This condition is associated with an increase in metabolic and cardiovascular diseases. Its cause is multifactorial, influenced by the environment, excessive calorie consumption, insufficient physical activity, sedentary lifestyle and alterations in energy metabolism.
In this context, the hormone leptin, responsible for regulating appetite and body weight, presents resistance in people with obesity, altering the metabolic balance. Recent research has explored the concept of the "gravitostat", a system that responds to the mechanical stimulus of standing upright, as a promising approach in the regulation of body weight. Animal and human studies have shown positive results in weight loss and body recomposition using this system. However, more research is needed to evaluate the clinical applicability and effectiveness of the gravitostat in the management of obesity.
For this reason, the present study is proposed, with a prospective longitudinal controlled design in the use of external body weight (where the patients are their own control: intrasubject controlled study) during 4 weeks, with a previous control period of 4 weeks and a follow-up of 4 weeks. The proposed objectives are to analyze the effectiveness of the use of external weight in the regulation of body weight, body composition and analytical parameters in people with grade II and III obesity. In this way, to analyze the clinical applicability of the gravitostat in the management of patients with this metabolic pathology.
Detailed description
BACKGROUND Obesity is one of the most prevalent and booming health and social problems in recent decades in industrialized societies. Obesity rates in European countries such as the United Kingdom, Germany, France and Spain fluctuate between 23 and 29% in the adult population, according to the World Health Organization (WHO). These values increase to 42.4%, 27% and 31% in the United States, Canada and Australia, respectively, considering data from the last 5 years from the main health agencies of these countries, making it a social and public health problem.
The etiopathogenesis of this condition is multifactorial; the obesogenic characteristics of the environment can influence gene expression conditioning the development of obesity. Increased caloric intake, influenced by high-fat diets (Westerns\' diet), the absence or insufficiency of physical activity and alterations in energy metabolism seem to be the three fundamental factors contributing to the development of obesity. Moreover, these factors seem to play a major role in the development of other metabolic entities such as hypertension, dyslipidemia and insulin resistance or type II diabetes, which, together with central obesity, make up the metabolic syndrome. This clinical entity doubles the risk of coronary and cerebrovascular disease, increases the risk of diabetes fivefold, and increases all-cause mortality by 50%. In parallel to the risk factors listed above, some studies highlight the role of a sedentary lifestyle as a factor independent of physical activity in contributing to the development of metabolic pathology. Not only the absence of low, moderate or high intensity physical activity has been correlated with the development of metabolic syndrome, but also the increase in time spent in sedentary activities, with an odds ratio of 2.38.
These intrinsic and extrinsic factors seem to interact and condition each other, altering homeostatic and physiological processes in obese individuals.
Since its discovery and description in the 1990s by Friedman leptin has been the most important hormonal factor in the regulation and control of caloric intake and metabolism, and consequently of body weight and composition. Its peripheral production at the level of white fat tissue and its hypothalamic effects (decrease in orexic neuronal activity and conditioning of dopaminergic reward circuits) condition the individual\'s response to food, regulating satiety and intake.
Evidence shows that this mechanism is altered in people with obesity where excessive leptin production, due to increased concentrations of fat tissue, and consequently high serum concentrations, condition central and peripheral sensitivity to this hormone, generating, in the long run, lower response efficiency, giving rise to the term "leptin resistance ". This resistance seems to modify the hypothalamic satiety signal, as well as the dopaminergic circuits associated with food intake,predisposing to the appearance or increase of metabolic pathology, especially obesity. This dysregulation in caloric intake appears without alterations in the production and function of ghrelin, a hormone produced in the stomach associated with hunger.
Recent research has proposed a second system of body weight homeostasis associated with the mechanical stimulus of standing upright, coined the term "gravitostat ".
Studies in mice and in humans show promising results in the regulation of body weight and fat percentage by this mechanical system. These investigations have shown significant reductions in both parameters when external weight is added to the study subjects, generating modifications in food intake and caloric expenditure. These adaptations have been tested independently of leptin resistance or the lack of leptin receptors, thus demonstrating the existence of an independent homeostatic regulation pathway. These changes have been shown to be significant only in obese subjects, whereas in normopese subjects, who show greater sensitivity to leptin, the changes produced by the increased load do not appear to be significant. Regarding body recomposition, these studies seem to indicate a maintenance of muscle mass, without experiencing significant losses, as in other contexts of caloric deficit thus prioritizing the loss of white fat tissue (especially visceral) as a mechanism of weight regulation.
Some studies justify this action by the production of fibroblast growth factors (FGF) produced by the osteocytes, specifically, the factor FGF21 associated with the hypothalamic receptor FGFR1c. The triplication in the serum quantities of FGF21 factor, by hepatic expression, in subjects exposed to body weight, seems to justify the increase in fat mobilization and oxidation, as well as the loss of body weight, which, despite the catabolic context, does not affect muscle mass. In any case, the results do not yet seem to be conclusive, since at supraphysiological loads of FGF21 the action of weight loss is mitigated, probably indicating a regulation by the FGFR1c receptor mediated, in part, by one or more other factors. This could be a key factor in the lack of effectiveness in normopese individuals.
Some stuides show how the increased load during the prepubertal period in rats reduces the expression of hormones associated with growth (IGF-1 and GHGH) as a homeostatic mechanism to control sudden weight gain. Similarly, down-regulation of ghrelin receptors at the hypothalamic level is observed, leading to a decrease in caloric intake. Other adaptations that could explain the physiological mechanism of body homeostasis, in this case, during growth.
With respect to analytical parameters, the only clinical trial carried out in humans only shows significant reductions in LDL and leptin; the results are inconclusive for the other parameters studied.
Taking this into consideration, some evidence observed a bidirectional regulation, with increases in body weight and fat mass in subjects with the sudden decrease in load. The lack of follow-up in human studies4 does not allow extrapolation of these results. At the clinical level, this regulation could justify weight and, essentially, fat gain after liposuction interventions6 or other contexts of abrupt weight loss or dietary patterns with aggressive caloric restriction. In this case, both homeostatic systems would influence, on the one hand, the gravitostat would increase food intake and the decrease in adipose tissue and the conditioned reduction in leptin production would decrease anorexic signals, predisposing the subjects to have more frequent and calorically dense intakes.
The results presented by some reserchers are promising in the development of new tools to help patients with obesity, despite this, the short duration of the intervention and the lack of follow-up of the patients, the lack of consistent changes in the analytical analysis, the performance only in young and moderately obese patients, as well as the high demand of the intervention protocol and the sudden gain in body weight after the intervention (in basic studies) make further research necessary to prove the applicability, usefulness and effectiveness of the gravitostat as a therapeutic tool, as well as the high demands of the intervention protocol and the sudden gain of body weight after the intervention (in basic studies) make it necessary to carry out further research to prove the applicability, usefulness and effectiveness of the gravitostat as a therapeutic tool in patients with obesity.
For this reason, the present doctoral thesis proposes an intrasubject controlled study for a period of 12 weeks (4 control, 4 intervention and 4 follow-up) in patients with grade II and III obesity. During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention, they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle.
For this study, accepting an alpha risk of 0.05 and a beta risk of less than 0.2 in a unilateral contrast, 24 patients are required to detect a difference equal to or greater than 0.15 unit. A common standard deviation of 1.4 and a correlation between the first and second measurement of 0.99 (according to literature) is assumed. A loss rate of 10% is assumed. Patients will be recruited from the endocrinology service of the Hospital Universitario Parc Taulí.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A prospective longitudinal controlled design on the use of external body weight (where patients are their own control: intrasubject controlled study) for 4 weeks, with a 4-week pre-control period and a 4-week follow-up.
| Arm | Type | Receives |
|---|---|---|
| Intervention Group (IG) | Experimental | Device: Weighted vestDuring the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age\>18 years
- BMI (≥35)
- Compliance at intervention delivery.
Key exclusion criteria (9 listed)
- Chronic pathology that may hinder the performance of the intervention
- Chronic pain
- Regular consumption of pharmacology or supplementation that affects body weight
- Inability to perform any physical activity or high risk of suffering adverse effects from the interventibariatric-metabolic surgery
- Reduced mobility
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Weighted vestAlso: External loadDuring the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest. | Device | Intervention Group (IG) |
Primary outcome
Body weight
Time frame: From enrollment to the end of treatment at 12 weeks
Measured fasting weight by electronic scale (BC-545N Tanita)
11 secondary outcomes
Nutritional state
Time frame: From enrollment to the end of treatment at 12 weeks
Grip Strength
Time frame: From enrollment to the end of treatment at 12 weeks
Lower Extremity Strength
Time frame: From enrollment to the end of treatment at 12 weeks
Activity state
Time frame: From enrollment to the end of treatment at 12 weeks
Absolute frequency of patients reporting adverse effects
Time frame: From week 4 to the end of treatment at 12 weeks
Body compostiton
Time frame: From enrollment to the end of treatment at 12 weeks
Body compostiton
Time frame: From enrollment to the end of treatment at 12 weeks
Age
Time frame: Baseline
Sex
Time frame: Baseline
Height
Time frame: Baseline
Body Mass Index
Time frame: Baseline
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2024.
- Results publication: PubMed 30888399Palsdottir V, Windahl SH, Hagg DA, Keantar H, Bellman J, Buchanan A, Vaughan TJ, Linden D, Jansson JO, Ohlsson C. Interactions Between the Gravitostat and the Fibroblast Growth Factor System for the Regulation of Body Weight. Endocrinology. 2019 May 1;160(5):1057-1064. doi: 10.1210/en.2018-01002.
- Results publication: PubMed 34240761Bake T, Peris-Sampedro F, Waczek Z, Ohlsson C, Palsdottir V, Jansson JO, Dickson SL. The gravitostat protects diet-induced obese rats against fat accumulation and weight gain. J Neuroendocrinol. 2021 Aug;33(8):e12997. doi: 10.1111/jne.12997. Epub 2021 Jul 9.
- Results publication: PubMed 33693673Jansson JO, Dalmau Gasull A, Schele E, Dickson SL, Palsdottir V, Palmquist A, Girones FF, Bellman J, Anesten F, Hagg D, Ohlsson C. A Body Weight Sensor Regulates Prepubertal Growth via the Somatotropic Axis in Male Rats. Endocrinology. 2021 Jun 1;162(6):bqab053. doi: 10.1210/endocr/bqab053.
- Results publication: PubMed 29279372Jansson JO, Palsdottir V, Hagg DA, Schele E, Dickson SL, Anesten F, Bake T, Montelius M, Bellman J, Johansson ME, Cone RD, Drucker DJ, Wu J, Aleksic B, Tornqvist AE, Sjogren K, Gustafsson JA, Windahl SH, Ohlsson C. Body weight homeostat that regulates fat mass independently of leptin in rats and mice. Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):427-432. doi: 10.1073/pnas.1715687114. Epub 2017 Dec 26.
- Results publication: PubMed 29800288Ohlsson C, Hagg DA, Hammarhjelm F, Dalmau Gasull A, Bellman J, Windahl SH, Palsdottir V, Jansson JO. The Gravitostat Regulates Fat Mass in Obese Male Mice While Leptin Regulates Fat Mass in Lean Male Mice. Endocrinology. 2018 Jul 1;159(7):2676-2682. doi: 10.1210/en.2018-00307.
- Results publication: PubMed 32510046Ohlsson C, Gidestrand E, Bellman J, Larsson C, Palsdottir V, Hagg D, Jansson PA, Jansson JO. Increased weight loading reduces body weight and body fat in obese subjects - A proof of concept randomized clinical trial. EClinicalMedicine. 2020 Apr 30;22:100338. doi: 10.1016/j.eclinm.2020.100338. eCollection 2020 May.
- Results publication: PubMed 26120842Ekblom O, Ekblom-Bak E, Rosengren A, Hallsten M, Bergstrom G, Borjesson M. Cardiorespiratory Fitness, Sedentary Behaviour and Physical Activity Are Independently Associated with the Metabolic Syndrome, Results from the SCAPIS Pilot Study. PLoS One. 2015 Jun 29;10(6):e0131586. doi: 10.1371/journal.pone.0131586. eCollection 2015.
- Results publication: PubMed 32272653Gallardo-Alfaro L, Bibiloni MDM, Mascaro CM, Montemayor S, Ruiz-Canela M, Salas-Salvado J, Corella D, Fito M, Romaguera D, Vioque J, Alonso-Gomez AM, Warnberg J, Martinez JA, Serra-Majem L, Estruch R, Fernandez-Garcia JC, Lapetra J, Pinto X, Garcia Rios A, Bueno-Cavanillas A, Gaforio JJ, Matia-Martin P, Daimiel L, Mico-Perez RM, Vidal J, Vazquez C, Ros E, Fernandez-Lazaro CI, Becerra-Tomas N, Gimenez-Alba IM, Zomeno MD, Konieczna J, Compan-Gabucio L, Tojal-Sierra L, Perez-Lopez J, Zulet MA, Casanas-Quintana T, Castro-Barquero S, Gomez-Perez AM, Santos-Lozano JM, Galera A, Basterra-Gortari FJ, Basora J, Saiz C, Perez-Vega KA, Galmes-Panades AM, Tercero-Macia C, Sorto-Sanchez C, Sayon-Orea C, Garcia-Gavilan J, Munoz-Martinez J, Tur JA. Leisure-Time Physical Activity, Sedentary Behaviour and Diet Quality are Associated with Metabolic Syndrome Severity: The PREDIMED-Plus Study. Nutrients. 2020 Apr 7;12(4):1013. doi: 10.3390/nu12041013.
- Results publication: PubMed 32422162Berthoud HR, Morrison CD, Munzberg H. The obesity epidemic in the face of homeostatic body weight regulation: What went wrong and how can it be fixed? Physiol Behav. 2020 Aug 1;222:112959. doi: 10.1016/j.physbeh.2020.112959. Epub 2020 May 16.
Related trials for Obesity Prevention
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Overweight, Prediabetic State
Recruiting
Evaluation of Impaired Mobility in Chronic Illness Constitution of a Cohort
Joint Osteoarthritis, Atherosclerosis of the Distal Arteries, Without Gangrene
Recruiting
National Childhood Obesity Prevention Programme BE FIT 24
Childhood Obesity
RecruitingPhase 3
Weight Gain Prevention in Adolescents and Young Adults
Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maria Assumpta Caixàs Pedragós, PhD, MD principal investigator
Consorci Sanitari Parc Taulí
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Weighted vest in people with Obesity Prevention and Obesity, run by Escoles Universitaries Gimbernat at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Manuel Garcia-San-Emeterio, PhD Student (Spain: +34689608040, manuel.garcias@eug.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body weight (time frame: From enrollment to the end of treatment at 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06619028, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.